Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
oleh: Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung-Soo Yoon, Manuel Praga
| Format: | Article |
|---|---|
| Diterbitkan: | BMC 2021-02-01 |
Deskripsi
An amendment to this paper has been published and can be accessed via the original article.